secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001708599-25-000016
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics appoints Dr. Jay Venkatesan to board; Dr. Milton Harris becomes Director Emeritus
--------------------------------------------------------------------------------

- Dr. Jay Venkatesan appointed to Board effective Feb 12, 2025; will serve as Audit Committee Chair and on Nominating/Governance Committee.
- Venkatesan previously co-founded Alpine Immune Sciences (acquired by Vertex for $4.9B) and served as CEO of Angion Biomedica.
- Dr. Milton Harris departs board effective Feb 11, 2025, becomes Director Emeritus and Chair of Scientific Advisory Board.
- Harris is co-founder, instrumental in POZ Platform; departure not due to any disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/ser-20250211.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer